China Pharma Holdings, Inc. (CPHI) News

China Pharma Holdings, Inc. (CPHI): $0.35

0.00 (1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CPHI to Watchlist
Sign Up

Industry: China


Ranked

of 49

in industry

Filter CPHI News Items

CPHI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CPHI News From Around the Web

Below are the latest news stories about CHINA PHARMA HOLDINGS INC that investors may wish to consider to help them evaluate CPHI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

William White on InvestorPlace | March 1, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off Monday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!

William White on InvestorPlace | February 27, 2023

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203.

Yahoo | February 24, 2023

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask").

Yahoo | December 28, 2022

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022.

Yahoo | December 15, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | December 6, 2022

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project.

Yahoo | December 5, 2022

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NYSE American") stating that the Company was not in compliance with a certain NYSE American continued listing standard relating to stockholders' equity, or Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer to have sto

Yahoo | December 2, 2022

China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency

China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") informing it that the Company is not in compliance with certain NYSE American continued listing standards (the "Listing Standards"). The Deficiency Letter indicated that the Company's securities had been selling for a low price per share for a substantial period of time and, most recen

Yahoo | October 2, 2022

China Pharma Announced the Submission of a Plan of Compliance to NYSE American

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the "Exchange") to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022 (the "Letter").

Yahoo | July 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7801 seconds.